The European Cancer Congress (ECC 2015) combined the efforts of the most important European oncology professionals with the aim of improving the prevention, diagnosis, treatment and care of cancer patients. Partner organisations included: ECCO, ESMO, ESTRO, ESSO, EACR, EONS and SIOPE representing a multidisciplinary approach to cancer treatment and care.
Held in Vienna on September 25-29 many of our NET Community, patients and clinicans, attended to hear about the much anticipated results of two International NET clinical trials.
NETTER-1 Clinical Trial
Professor Philippe Ruszniewski, MD, Head of the Department of Gastroenterology-Pancreatology, Beaujon Hospital, Clichy, France, who is also a Professor at Paris Diderot University, told the Congress that results of the NETTER-1 phase III trial of 177Lu-DOTATATE (Lutathera) show a Progression Free Survival that has never been shown before in this type of cancer. "Because these patients have a real unmet medical need, this is particularly pleasing for us," he says.
Click on this link to read full details http://www.esmo.org/Conferences/European-Cancer-Congress-2015/News/Rare-cancer-responds-unusually-well-to-new-treatment-results-from-the-NETTER-1-trial
RADIANT – 4 Trial
An international team of researchers has shown that the use of the mTOR inhibitor , everolimus, can delay tumour growth among both gastrointestinal and lung NETs. This is particularly important for patients with the lung tumours, the researchers say, because there is currently no approved treatment for such cases. Results for the trial were presented by Professor Jame Yao of the MD Anderson Cancer Centre in Houston USA.
Click here for more details http://www.esmo.org/Conferences/European-Cancer-Congress-2015/News/Results-of-International-Trial-Show-Promise-in-Rare-Difficult-to-Treat-Cancer-results-from-the-RADIANT-4-trial
The Unicorn Foundation and the global NET Patient community is heartened by these results, and encourage greater collaboration and continued support of NET trials such as CONTROL NETs, to build the body of evidence for treatments in NETs.